Head to Head Contrast: USANA Health Sciences (NYSE:USNA) & NLS Pharmaceutics (NASDAQ:NCEL)

NLS Pharmaceutics (NASDAQ:NCEL) and USANA Health Sciences (NYSE:USNA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation.

Valuation and Earnings

This table compares NLS Pharmaceutics and USANA Health Sciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$1.98 million	N/A	N/A
USANA Health Sciences	$912.67 million	0.41	$42.03 million	$0.88	23.11

USANA Health Sciences has higher revenue and earnings than NLS Pharmaceutics.

Institutional and Insider Ownership

54.3% of USANA Health Sciences shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by company insiders. Comparatively, 0.6% of USANA Health Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for NLS Pharmaceutics and USANA Health Sciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1	0	0	0	1.00
USANA Health Sciences	1	3	0	0	1.75

USANA Health Sciences has a consensus price target of $36.00, suggesting a potential upside of 76.99%. Given USANA Health Sciences’ stronger consensus rating and higher possible upside, analysts plainly believe USANA Health Sciences is more favorable than NLS Pharmaceutics.

Profitability

This table compares NLS Pharmaceutics and USANA Health Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
USANA Health Sciences	1.86%	6.97%	5.00%

Volatility & Risk

NLS Pharmaceutics has a beta of 0.12, meaning that its stock price is 88% less volatile than the S&P 500. Comparatively, USANA Health Sciences has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500.

Summary

USANA Health Sciences beats NLS Pharmaceutics on 9 of the 10 factors compared between the two stocks.

About NLS Pharmaceutics

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

About USANA Health Sciences

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products through retail stores and online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.